Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$10.9 million.

  • Silence Therapeutics' Free Cash Flow rose 57.53% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.6 million, marking a year-over-year decrease of 56.96%. This contributed to the annual value of -$67.9 million for FY2024, which is 37.02% down from last year.
  • Per Silence Therapeutics' latest filing, its Free Cash Flow stood at -$10.9 million for Q3 2025, which was up 50.08% from -$21.8 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Free Cash Flow ranged from a high of $36.4 million in Q2 2021 and a low of -$27.5 million during Q4 2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$12.3 million (2025), whereas its average is -$15.4 million.
  • As far as peak fluctuations go, Silence Therapeutics' Free Cash Flow skyrocketed by 73.28% in 2021, and later crashed by 429.09% in 2022.
  • Silence Therapeutics' Free Cash Flow (MRQ) stood at -$3.0 million in 2021, then crashed by 429.09% to -$15.7 million in 2022, then tumbled by 42.66% to -$22.4 million in 2023, then fell by 22.76% to -$27.5 million in 2024, then soared by 60.41% to -$10.9 million in 2025.
  • Its last three reported values are -$10.9 million in Q3 2025, -$21.8 million for Q2 2025, and -$12.3 million during Q1 2025.